Peter Blume-Jensen
2023
In 2023, Peter Blume-Jensen earned a total compensation of $6.5M as Chief Executive Officer, President and Director at Acrivon Therapeutics, a 70% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $348,700 |
|---|---|
| Salary | $629,000 |
| Stock Awards | $5,488,273 |
| Total | $6,465,973 |
Blume-Jensen received $5.5M in stock awards, accounting for 85% of the total pay in 2023.
Blume-Jensen also received $348.7K in non-equity incentive plan and $629K in salary.
Rankings
In 2023, Peter Blume-Jensen's compensation ranked 62nd out of 2,937 executives tracked by ExecPay. In other words, Blume-Jensen earned more than 97.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 62 out of 2,937 | 98th |
Division Manufacturing | 30 out of 1,622 | 98th |
Major group Chemicals And Allied Products | 22 out of 904 | 98th |
Industry group Drugs | 21 out of 867 | 98th |
Industry Pharmaceutical Preparations | 14 out of 625 | 98th |
Source: SEC filing on April 26, 2024.
Blume-Jensen's colleagues
We found two more compensation records of executives who worked with Peter Blume-Jensen at Acrivon Therapeutics in 2023.